Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 12, 2022
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

August 12, 2022
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

August 01, 2022
Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody

June 28, 2022
Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis

June 27, 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors

June 21, 2022
Chemomab Therapeutics to Present at June Investor and Scientific Conferences

June 09, 2022
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022

June 02, 2022
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 18, 2022
Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022